Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (NCT03049189), a randomized phase 3 study. The primary outcome is Progression-Free Survival (PFS).

2. Clinical Question

3. Trial Design

This was a prospective, randomized, controlled, open-label, multicentre Phase III study. Participants were assigned to a parallel treatment group: 177Lu-edotreotide PRRT or Everolimus. The registry records 324 enrolled participants and an active, not recruiting status. The recorded study start was 2017-02-02, and the primary completion date was 2024-11-27.

The treatment schedules differed. The PRRT arm was described as receiving up to four cycles of 177Lu-edotreotide, with each cycle 90 days apart and a total treatment duration of 270 days/9 months. Everolimus was described as continuous daily oral treatment until progression or the end of the study. Amino-Acid Solution is also listed as an intervention, but its role in the treatment schedule is not reported in the registry record.

The primary progression-free survival analysis was based on the full analysis set, identified as 309 randomized participants. The registry’s arm-specific primary outcome entries list 207 participants for 177Lu-edotreotide PRRT and 102 for Everolimus. The objective response rate entries use different analysis counts: 201 and 95, respectively. The reasons for the differing analysis counts are not reported in the registry record.

Although treatment assignment was open-label, progression for the primary endpoint was evaluated by blinded independent central review. This distinction matters: participants and treatment teams knew the assigned treatment, while the stated central assessment of progression was blinded. The registry does not report further details about the randomization procedure, allocation concealment, or the handling of treatment changes.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: The COMPETE protocol included Sub-Study C, to evaluate PK urine analysis and bone marrow dosimetry for 177Lu-edotreotide. Sub-Study C enrolled participants from the 177Lu-edotreotide arm of the COMPETE study and a non-randomized cohort. All participants in Sub-Study C received 177Lu-edotreotide.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: PFS analysis is based on the FAS population, i.e., 309 participants randomized in the COMPETE study. The COMPETE protocol included a Sub-Study C, to evaluate PK urine analysis and bone marrow dosimetry. Sub-Study C enrolled participants from the 177Lu-edotreotide arm of the COMPETE study and a non-randomized cohort. Participants from the non-randomized cohort were not included in the FAS.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The baseline demographics are summarized for the Full Analysis Set (FAS), encompassing 309 participants, included all who were randomized to treatment and was used for all efficacy analyses.

6. Primary Endpoint

The registry lists the primary outcome as Progression-Free Survival (PFS), measured over From date of randomization until the date of first documented progression or death, assessed up to 30 months,.

Progression-free survival measures the time from randomization to the first documented tumour progression or death. In this trial, progression was determined using RECIST criteria v1.1 and evaluated by blinded independent central review. The endpoint therefore combines two types of events: documented progression and death. A participant without either event by the end of available follow-up would generally contribute information up to the point at which follow-up ended, but the registry’s censoring rules are not reported in the registry record.

Time-to-event outcomes are useful when the timing of an event matters and participants may have different lengths of follow-up. They use information about when events occur, rather than simply comparing the proportion of participants with an event at one fixed time. The registry reports median progression-free survival for each group and a hazard ratio for the randomized comparison. The median is the estimated time by which half of the relevant group has experienced the endpoint; it is not a guarantee about an individual participant’s outcome.

Central review can help standardize progression assessment across an open-label trial, since knowledge of assigned treatment may otherwise influence how outcomes are assessed. The registry does not report details of the review process beyond its blinded, independent status, or whether other endpoint-assessment safeguards were used.

7. Results Posted in the Registry

• 177Lu-edotreotide PRRT vs Everolimus: hazard ratio 0.67 (95% CI 0.48–0.95), reported p = 0.022 (as reported in the registry).

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Objective Response Rate (ORR)

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Everolimus: 4.2% (4/95) versus 21.9% (44/201) on control; risk difference -17.7 percentage points (95% CI -24.7 to -10.7), risk ratio 0.19 (0.07–0.52); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Everolimus than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The registry names objective response rate and overall survival as secondary outcomes. The posted numerical secondary results include objective response rate; numerical overall-survival results are not reported in the registry record. The secondary evidence is therefore incomplete for assessing the full set of named outcomes.

At a broad level, the available secondary outcome points in the same general direction as the primary progression-free survival comparison: the posted response result favors the PRRT group in the recorded analysis. That consistency can add context, but response and progression-free survival measure different aspects of outcome. A response is a binary assessment over a stated period, whereas progression-free survival incorporates time to progression or death. Agreement in direction does not make the endpoints interchangeable, and the secondary result does not independently establish the primary time-to-event finding.

Secondary outcomes are commonly interpreted with less weight than the primary endpoint, particularly when several outcomes or comparisons are considered. Testing multiple hypotheses increases the chance that at least one result appears notable by chance. The registry does not report a multiplicity adjustment or a testing hierarchy for the secondary outcomes, so the p-value for response should be viewed as unadjusted unless further analysis details are reported elsewhere in the registry record.

The result for response is also based on a smaller analysis count than the primary outcome: the registry lists 201 participants for the PRRT group and 95 for Everolimus for this endpoint. The reasons for these analysis counts, and the missing-response handling, are not reported in the registry record. Such information matters when interpreting a percentage because the denominator and the way unavailable assessments are treated affect what the percentage represents.

Overall, the secondary results provide limited corroborating context rather than a complete independent confirmation. The absence of numerical overall-survival results and unreported details about multiplicity and missing data limit conclusions from the secondary outcome set.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Objective Response Rate (ORR)
• Overall Survival (OS)

9. Statistical Interpretation

10. Statistical Methods Explained

What does the median represent?

For a time-to-event endpoint, the median is the estimated time at which the event-free proportion has reached one half. Here, the event is progression or death. A median is a distribution-level summary: it does not mean that all participants experience an event at that time, and it does not describe the timing for any one participant. The registry gives a median and a confidence interval for each randomized group.

The reported medians are 23.9 months for 177Lu-edotreotide PRRT and 14.1 months for Everolimus. These summaries use the registry’s full analysis set of 309 randomized participants, with 207 listed in the PRRT arm and 102 in the Everolimus arm. The registry does not state the number of progression-or-death events underlying the primary analysis or give the follow-up distribution.

How should a hazard ratio be read?

A hazard is the event rate among participants who have not yet experienced the event, considered over follow-up. In general, a hazard ratio compares those rates between groups. The sponsor-reported hazard ratio of 0.673 compares 177Lu-edotreotide PRRT with Everolimus. Its value is a relative measure, not a difference in months, and it is not a direct estimate of the probability that a participant will experience progression or death by a particular date.

Hazard-ratio interpretation can depend on how the relative event rates behave over time. If the relative rates change substantially during follow-up, one overall hazard ratio may not describe every period equally well. Whether that assumption was assessed, and what methods were used if it was not met, are not reported in the registry record. The result is reported using a Log Rank method, but the registry does not provide further detail about the estimation procedure or diagnostic checks.

What does the Log Rank result convey?

The Log Rank test is a general method for comparing time-to-event experience between groups while taking account of event timing and follow-up. The reported p-value is 0.022. In general, a p-value measures how compatible the observed data are with a specified null hypothesis, assuming the analysis conditions hold. It is not the probability that the null hypothesis is true, and it does not quantify the clinical importance of the result. The registry does not report whether any additional time-to-event tests or sensitivity analyses were conducted.

The registry labels the primary comparison as superiority and reports a hazard ratio with a 95% confidence interval. No discrepancy between the sponsor analysis and the posted comparison is indicated. The sponsor’s reported estimate and test should therefore be distinguished from any simple re-analysis of summary information; no recalculated primary hazard ratio is presented in the registry record.

Why does over-dispersion matter in general?

For count data, over-dispersion means that variability is greater than expected under a simple model such as a Poisson distribution. When that occurs, a model that assumes less variability can make standard errors too small and confidence intervals too narrow. This is a general statistical consideration, not a feature reported for this trial’s primary time-to-event analysis. The primary outcome is a time-to-event endpoint, and the registry does not describe a count model for it.

How do binary-outcome comparisons differ?

Objective response rate is a binary endpoint: each participant is categorized as having or not having a recorded response over the stated period. The registry reports group percentages and confidence intervals, and lists a Mantel Haenszel analysis with a p-value of < 0.001. A simple unadjusted re-calculation from the posted summary counts yields a p-value of <0.001. These are not identical analysis procedures or necessarily identical tests; the sponsor’s own analysis is the primary reported result.

For binary outcomes, differences in proportions, risk ratios, and odds ratios answer related but distinct questions. The registry’s unadjusted re-calculation includes a risk difference and interval, and also reports relative measures. Such re-calculations use the posted summary counts without adjustment for other variables. The registry does not report the full adjustment details for the sponsor’s Mantel Haenszel analysis, so the results should not be assumed to have used identical covariate handling.

11. Confidence Intervals and Precision

The 95% confidence intervals express statistical uncertainty around the estimated group medians and hazard ratio. In general, a confidence interval is a range produced by a method that, under its assumptions, would cover the target quantity at the stated rate over repeated studies. It is not a range containing 95% of participant outcomes, nor does it assign a 95% probability to the particular fixed parameter after the data have been observed.

For 177Lu-edotreotide PRRT, the median progression-free survival estimate is 23.9 months, with a 95% confidence interval from 18.7 to 30.0 months. For Everolimus, the estimate is 14.1 months, with a 95% confidence interval from 9.2 to 20.9 months. The hazard ratio is 0.673, and its 95% confidence interval runs from 0.477 to 0.948. The interval gives a range of plausible values under the stated analysis, while the point estimate gives one central estimate. It does not convey all uncertainty about study design, follow-up, or applicability.

Confidence intervals for group-specific medians and for a hazard ratio describe different quantities. They should not be compared as though they were intervals for the same contrast. The hazard-ratio interval directly concerns the relative event rate, while each median interval concerns a group’s estimated event-free time distribution. The registry does not report confidence intervals for every other outcome or details of the interval-calculation procedures.

Precision is influenced by the amount and timing of information available, including the number of participants and the number of observed events. The primary analysis population is stated, but the number of primary events and the distribution of follow-up are not reported in the registry record. As a result, the displayed intervals can be described, but the underlying event information cannot be fully assessed from this record alone.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size entries are planning illustrations based on the observed effect, not the trial’s original design assumptions. For the time-to-event outcome, the entries are total numbers of events, not participants per arm. For the other outcome, they are participants per arm. The planning assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; each scenario uses the stated fraction of the observed effect. The trial’s own original sample-size assumptions are not reported in the registry record.

For the time-to-event illustration, planning for 100% of the observed effect gives 201 total events for 80% power and 269 total events for 90% power. Planning for 75% of the observed effect gives 356 total events for 80% power and 477 total events for 90% power. Planning for 50% of the observed effect gives 801 total events for 80% power and 1,073 total events for 90% power.

For the binary-outcome illustration, planning for 100% of the observed effect gives 56 participants per arm for 80% power and 75 participants per arm for 90% power. Planning for 75% of the observed effect gives 115 participants per arm for 80% power and 153 participants per arm for 90% power. Planning for 50% of the observed effect gives 289 participants per arm for 80% power and 386 participants per arm for 90% power.

In plain language, the 80% and 90% columns describe the chance a study designed under these assumptions would detect the specified effect at the stated significance level, if that effect were true. Smaller effects need more participants or, for the time-to-event illustration, more events. These figures are not observed power.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

d is the total number of events needed (Schoenfeld's formula) with 1:1 allocation and proportional hazards.

Worked calculation for this trial

1. Hazard ratio HR = 0.673, so ln(HR) = -0.3960.
2. d = 4 × (1.96 + 0.842)² / [ln(0.673)]² = 200.2, rounded up to 201 events in total for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
hr <- 0.673                              # observed hazard ratio
events_needed <- function(power, frac = 1) ceiling(round(4 * (z_a + qnorm(power))^2 / log(hr^frac)^2, 6))   # Schoenfeld, 1:1 allocation
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: events = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(events_needed(0.80, f), big.mark = ","), format(events_needed(0.90, f), big.mark = ",")))

# Simulation: given d total events under proportional hazards, events in the treatment arm are Binomial(d, hr / (1 + hr)).
# The score (log-rank type) statistic is (D1 - d / 2) / sqrt(d / 4).
set.seed(3049189)
d    <- events_needed(0.80)
reps <- 20000
D1 <- rbinom(reps, d, hr / (1 + hr))
z  <- (D1 - d / 2) / sqrt(d / 4)
cat(sprintf("Simulated power with %s events: %.3f (%d replicates)\n", format(d, big.mark = ","), mean(abs(z) > z_a), reps))

Output from running the code

100% of observed effect: events = 201 (80% power), 269 (90% power)
 75% of observed effect: events = 356 (80% power), 477 (90% power)
 50% of observed effect: events = 801 (80% power), 1,073 (90% power)
Simulated power with 201 events: 0.793 (20000 replicates)

The simulation uses the fact that, with d events in total and proportional hazards, the number of events in the treatment arm is binomial. It is an approximation that conditions on the total number of events, and it should land close to the target power.

14. Group-Sequential Design Analysis

Many time-to-event trials, especially in oncology, stop or report early when interim data are overwhelming, so a single fixed-sample number understates the real design problem. The calculation below is an illustrative group-sequential design built from this trial's posted control median and hazard ratio. The registry record does not state the planned number of looks or the spending function, so the design is a planning illustration, not a reconstruction of the protocol. Assumed: one-sided α = 0.025, 90% power, three equally spaced looks on information, Lan-DeMets O'Brien-Fleming spending, 24 months of accrual, 60 months in total and a 1% monthly dropout hazard.

Under these assumptions the design needs about 374 participants in total, with the boundaries below.

Fixed design versus group-sequential alternatives

Group-sequential designs cost a small increase in maximum sample size and events compared with the fixed design, in exchange for the chance to stop early for overwhelming efficacy. O'Brien-Fleming spending keeps early boundaries very conservative and the final boundary close to the fixed-design value, whereas Pocock spending spends more alpha early.

Sensitivity to a smaller true effect

Planning for exactly the observed effect is optimistic, because observed effects in published trials tend to be somewhat larger than the true effect. The table repeats the main design (three looks, O'Brien-Fleming spending, 90% power) for smaller true hazard ratios.

For context, this trial enrolled 324 participants.

Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993. Agreement between the two packages confirms the boundary calculation.

R code and output

suppressWarnings(suppressMessages({ library(gsDesign); library(rpact) }))
med_control <- 14.1          # control-arm median, months (converted from the posted unit)
hr          <- 0.673          # hazard ratio used for planning
lambdaC     <- log(2) / med_control
eta         <- 0.01               # dropout hazard per month (assumption)
acc_months  <- 24                 # accrual duration (assumption)
study_months<- 60                 # total study duration (assumption)

design <- function(k, sfu, beta, h = hr) gsSurv(k = k, test.type = 1, alpha = 0.025, beta = beta, sfu = sfu,
  lambdaC = lambdaC, hr = h, hr0 = 1, eta = eta, gamma = 1, R = acc_months, T = study_months, minfup = study_months - acc_months)

# Main design: 3 looks, Lan-DeMets O'Brien-Fleming spending, one-sided alpha 0.025, 90% power
x <- design(3, sfLDOF, 0.10)
cat(sprintf("N_TOTAL|%s\n", format(ceiling(sum(x$gamma * x$R)), big.mark = ",")))
for (i in 1:3) cat(sprintf("GS|%d|%.1f|%.0f|%.3f|%.5f|%.5f\n", i, x$T[i], x$n.I[i], x$upper$bound[i], pnorm(-x$upper$bound[i]), cumsum(x$upper$spend)[i]))
cat("\n"); print(gsBoundSummary(x))

# Comparison of designs
cmp <- list(list("Fixed design, one analysis", 1, sfLDOF), list("Two looks, O'Brien-Fleming", 2, sfLDOF),
            list("Three looks, O'Brien-Fleming", 3, sfLDOF), list("Three looks, Pocock", 3, sfLDPocock))
cat("\n")
for (b in c(0.20, 0.10)) for (d in cmp) {
  y <- design(d[[2]], d[[3]], b)
  cat(sprintf("DES|%s|%d|%.0f|%s|%.1f\n", d[[1]], round(100 * (1 - b)), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ","), tail(y$T, 1)))
}

# Sensitivity: what if the true effect is smaller than the observed one? (3 looks, O'Brien-Fleming, 90% power)
cat("\n")
for (fr in c(1, 0.75, 0.5)) {
  y <- design(3, sfLDOF, 0.10, exp(log(hr) * fr))
  cat(sprintf("SENS|%.2f|%.3f|%.0f|%s\n", fr, exp(log(hr) * fr), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ",")))
}

# Independent cross-check of the boundaries with rpact
r <- getDesignGroupSequential(kMax = 3, alpha = 0.025, beta = 0.10, sided = 1, typeOfDesign = "asOF", informationRates = x$timing)
cat(sprintf("\nCross-check, upper boundaries: gsDesign %s | rpact %s\n", paste(round(x$upper$bound, 3), collapse = ", "), paste(round(r$criticalValues, 3), collapse = ", ")))

Method: LachinFoulkes 
    Analysis               Value Efficacy
   IA 1: 33%                   Z   3.7103
      N: 306         p (1-sided)   0.0001
  Events: 90        ~HR at bound   0.4573
   Month: 20    P(Cross) if HR=1   0.0001
             P(Cross) if HR=0.67   0.0338
   IA 2: 67%                   Z   2.5114
      N: 374         p (1-sided)   0.0060
 Events: 180        ~HR at bound   0.6877
   Month: 31    P(Cross) if HR=1   0.0060
             P(Cross) if HR=0.67   0.5603
       Final                   Z   1.9930
      N: 374         p (1-sided)   0.0231
 Events: 270        ~HR at bound   0.7846
   Month: 60    P(Cross) if HR=1   0.0250
             P(Cross) if HR=0.67   0.9000



Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993

15. Analyses Reported by the Sponsor

The sponsor’s primary analysis reports a hazard ratio of 0.673, with a 95% confidence interval from 0.477 to 0.948 and a Log Rank p-value of 0.022. These are the reported primary comparison results for progression-free survival. The registry does not flag a discrepancy between the sponsor analysis and the posted comparison.

The summary of the primary endpoint also includes group-specific medians. Those median estimates describe the time-to-event distributions in the two analysis groups; they are not recalculations of the sponsor’s hazard ratio. The hazard ratio is a relative comparison over follow-up, and it should be interpreted using the sponsor’s reported analysis rather than reconstructed from the medians.

For objective response rate, the sponsor’s reported Mantel Haenszel analysis gives a p-value of < 0.001. A simple unadjusted re-calculation from the posted response counts gives a p-value of <0.001. The two values reflect different analysis approaches and are not interchangeable. The sponsor’s own analysis takes precedence as the trial’s reported analysis. The registry does not provide enough detail to reproduce the Mantel Haenszel calculation or fully compare its adjustment choices with the unadjusted re-calculation.

Recalculated results are useful as checks based on the posted summary statistics, but they do not replace the sponsor’s prespecified analysis. In this record, the primary time-to-event comparison is represented by the sponsor-reported hazard ratio and test; the simple re-calculation applies to the binary response outcome.

16. Multiplicity, Missing Data and Analysis Populations

The registry identifies progression-free survival as the primary outcome and lists objective response rate and overall survival as secondary outcomes. It also reports more than one analysis. The registry record does not report a plan for controlling the family-wise chance of false positive findings across outcomes, a hierarchy for testing them, or a multiplicity adjustment. Without those details, the reported secondary p-value should not be treated as though it necessarily preserves the same error rate as a single prespecified test.

The registry does not report the trial’s full statistical analysis plan, including the intended handling of missing endpoint data, censoring rules for progression-free survival, or sensitivity analyses. Those methods can affect time-to-event and binary endpoint estimates. For example, censoring determines how information is used for a participant whose event time is not observed during follow-up. The endpoint description states that follow-up was assessed up to 30 months, but detailed censoring rules and the completeness of follow-up are not reported in the registry record.

The primary analysis population is described as the full analysis set, with 309 randomized participants. The response outcome lists 201 participants in the PRRT group and 95 in the Everolimus group. The reasons the response analysis counts differ from the primary analysis counts are not reported in the registry record. Nor are the rules for inclusion in the full analysis set, the handling of participants who did not receive assigned treatment, or the handling of missing response assessments described in detail.

The registry identifies a blinded independent central review for progression assessment, despite the open-label treatment assignment. This helps clarify the stated assessment approach, but does not by itself answer questions about missing scans, timing of assessments, adjudication procedures, or whether other analyses tested the robustness of the result.

These omissions do not invalidate the reported estimates, but they limit independent assessment of how analysis decisions may have influenced them. More detailed methods and outcome reporting would be needed to evaluate those issues fully.

17. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: acute kidney injury (5.1%), intestinal obstruction (3.0%), diabetes mellitus (3.0%), cholecystitis (2.3%), tricuspid valve incompetence (2.0%).

The registry reports serious adverse events in 66 of 217 participants at risk in the 177Lu-edotreotide PRRT group and 44 of 99 participants at risk in the Everolimus group. Other adverse events are reported for 204 of 217 and 98 of 99 participants, respectively. Deaths are listed for 14 participants in the PRRT group and 7 in the Everolimus group.

These are counts within the stated groups, not estimates of whether a treatment caused an event. The registry does not report in this summary whether the deaths were considered treatment-related, nor does it provide enough detail about event timing, exposure duration, or comparative statistical testing. The groups also have different numbers at risk, so the counts alone should not be read as a direct measure of relative safety.

The most frequently listed serious terms include acute kidney injury at 5.1%, intestinal obstruction at 3.0%, diabetes mellitus at 3.0%, cholecystitis at 2.3%, tricuspid valve incompetence at 2.0%, and disease progression at 2.0%. A listed serious event is not necessarily caused by the assigned treatment. These registry figures describe reported events; they do not by themselves establish causation or provide a complete benefit-harm assessment.

18. What the Result Does, and Does Not, Mean

The primary result is a randomized comparison of progression-free survival in participants with the study’s specified tumour characteristics. The registry reports longer median progression-free survival in the PRRT group than in the Everolimus group, along with a sponsor-reported hazard ratio below 1 and a 95% confidence interval that does not include 1. The reported Log Rank p-value is 0.022. These statistics describe the analyzed groups and the uncertainty in the estimated comparison.

The result does not mean that every participant in one group will have a longer time without progression or death than every participant in the other group. A group median and a hazard ratio summarize distributions across participants; they do not predict individual outcomes. Nor does the p-value indicate the probability that the treatment comparison is true or false.

The result also does not by itself establish the comparative effect on overall survival. Overall survival is named as a secondary outcome, but numerical results are not reported in the registry record. The response outcome provides another type of information, but it is not equivalent to a time-to-event outcome, and the registry does not report a multiplicity plan for the secondary analyses.

Generalizability depends on how closely a reader’s intended population and setting match the study population and its implementation. The registry describes inoperable, progressive, somatostatin receptor-positive neuroendocrine tumours of gastroenteric or pancreatic origin. The record does not provide subgroup estimates or enough detail to determine how the result varies across participant characteristics or clinical settings.

Finally, efficacy estimates should be considered alongside safety information and the limitations of the registry record. Serious adverse event counts and deaths are reported, but the details available do not establish causality or resolve comparative benefit and harm. The statistical findings are evidence about the study groups, not medical advice or a decision for an individual.

19. Why This Trial Matters Statistically

This trial is statistically notable for comparing two active treatment strategies in a randomized, parallel-group Phase III design, with progression-free survival as its primary endpoint. Randomization supports a comparative interpretation by balancing, on average, measured and unmeasured baseline characteristics, provided that the allocation and analysis are appropriately implemented. The registry confirms randomization but does not report all operational details needed to assess those conditions fully.

The primary endpoint combines progression and death and uses time-to-event information. That approach retains information about event timing and differing follow-up, rather than reducing the comparison to a single fixed-time proportion. The registry also states that progression was assessed by blinded independent central review. This is a relevant design feature in an open-label study, where participants and treatment teams knew the assigned group.

The report presents both group-specific median estimates and a comparative hazard ratio with a confidence interval. These statistics answer related but distinct questions: the medians describe each group’s time-to-event distribution, while the hazard ratio summarizes the relative event rate over follow-up. Understanding that distinction helps avoid treating a relative measure as a difference in months or as an individual prediction.

The record also illustrates why statistical evidence must be interpreted with its reporting context. The primary analysis is described more clearly than some secondary analyses, while details about multiplicity, missing data, sample-size design assumptions, and further sensitivity analyses are not reported in the registry record. The planning illustrations show how required information changes under different assumed effect sizes, but they are not a description of the trial’s original design calculation.

Overall, the trial provides a useful example of interpreting a randomized time-to-event comparison alongside secondary outcomes and safety counts, while keeping the limits of the registry’s methods reporting in view.

20. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this trial follow from the information available in the registry record. Although the study is described as randomized and open-label, details of the randomization sequence, allocation concealment, and any stratification factors are not reported. Treatment assignment was not masked, so expectations and care processes could potentially differ between groups. Blinded independent central review is specified for progression assessment, but other safeguards and review procedures are not described.

The primary endpoint is defined, but the number of progression-or-death events, follow-up distribution, censoring rules, and completeness of outcome ascertainment are not reported in the registry record. These details would help readers assess the information supporting the hazard ratio and the extent to which the estimate depends on follow-up choices. The registry also does not report an assessment of the assumptions relevant to the reported time-to-event analysis.

The full analysis set is identified as 309 randomized participants, while the response endpoint lists smaller analysis counts. The reasons for the differing counts and the handling of missing response data are not reported. Numerical results for overall survival are also not reported, limiting interpretation of the named secondary outcomes.

The registry does not report multiplicity procedures, the full statistical analysis plan, sensitivity analyses, subgroup estimates, or the trial’s original sample-size assumptions. The planning illustrations are based on the observed effects and should not be mistaken for those original design decisions. Finally, adverse event counts are available, but detail on attribution, timing, exposure, and comparative safety analyses is limited. These reporting gaps constrain independent assessment; they do not, by themselves, determine the direction or validity of the reported results.

21. Related Tutorials

22. Related Statistical Calculators

23. Sources

• ClinicalTrials.gov: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — NCT03049189.
• Registry record last updated 2026-10-20; status last verified 2026-07.
• Results first posted 2026-04-06.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

24. Record Summary

NCT03049189 is a randomized, open-label, parallel-group, multicentre Phase III study of 177Lu-edotreotide PRRT versus Everolimus in participants with inoperable, progressive, somatostatin receptor-positive GEP-NET. The registry records enrollment of 324 and active, not recruiting status. The primary outcome is progression-free survival, defined from randomization to documented progression or death, with progression assessed by blinded independent central review.

The full analysis set included 309 randomized participants. The sponsor-reported hazard ratio was 0.673, with a 95% confidence interval from 0.477 to 0.948 and a Log Rank p-value of 0.022. Objective response rate is listed as a secondary outcome, while numerical overall-survival results are not reported in the registry record. Details about multiplicity, missing-data methods, and the original sample-size assumptions are also not reported.